Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

News Conference News ESC 2021

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

Caitlin E. Cox

September 01, 2021

News Conference News ESC 2021

Studies Reveal Surprising Benefits of Smoking Cessation and ‘Greenness’

L.A. McKeown

August 28, 2021

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Presentation ESC 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presenter: Paul M. Ridker

August 27, 2017

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

Advertisement

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

Studies Reveal Surprising Benefits of Smoking Cessation and ‘Greenness’

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content